Earlier Detection.Zero Gaps.One Orchestrated Journey.
End-to-end AI for oncology care, from risk to recovery.
Qure.ai turns routine imaging and clinical data into an AI-enabled intelligence layer across the oncology journey detecting at risk patients earlier, tracking them through every handoff, and driving the guideline concordant actions that shift stage at diagnosis.
Meet the Qure team at ESMO Congress 2026 | Booth #8097
* To know more about our FDA-cleared AI indications, contact partner@qure.ai
* To know more about our FDA-cleared AI indications, contact partner@qure.ai
One Journey, Three Moves: Detect. Track. Act.
Oncology's toughest problem isn't a single point of failure-it's the handoffs. Qure.ai's AI works across the full pathway so no at-risk patient, no flagged finding, and no next step falls through the cracks.
Detect
Find disease earlier, at population scale.
AI-derived imaging biomarkers from chest radiographs, CT scans, radiology reports, and EMR data surface early signs of cancer risk-flagging high-risk and therapy-relevant patients before symptoms do. Early diagnosis, stage-shift opportunity, and scalable patient identification, built into routine care.
TRACK
Never lose a patient between the scan and the specialist.
By unifying imaging, clinical, and real-time EMR data, Qure.ai's multimodal clinical intelligence layer tracks every flagged patient through referral, work-up, and follow-up-generating real-world evidence along the way and closing the loop that today runs on spreadsheets and phone calls.
ACT
Turn insight into the next clinical decision, faster.
Agentic AI powers MDT-based care coordination and guideline-concordant decision support from diagnosis to treatment-reducing patient leakage, shortening time to treatment initiation, and keeping longitudinal tracking in place after the first intervention.
From Signal to Action: Across the Full Care Journey
Designed to create value across the life sciences continuum-from clinical development to commercialization.
Patient finding
Identify undiagnosed and at-risk populations across routine care settings.
Trial acceleration
Support cohort identification, feasibility, enrichment, and site readiness.
Treatment activation
Guide and track patients into appropriate care pathways with zero drop-offs.
Real-world evidence
Generate longitudinal insights across disease progression, care patterns, and outcomes.
Trusted by healthcare systems, proven by practice.
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
"Our collaboration with Qure.ai has validated the power of AI-enabled chest X-rays as a cost-effective triaging tool for early lung cancer detection. With successful implementation in countries such as Colombia, El Salvador, and India, we are setting the stage for scaling this approach."
Ti Hwei How
Ex-Vice President, Oncology Business Unit, International Markets
AstraZeneca
"Initial real-world studies and recent FDA clearances have provided compelling evidence for the potential of Qure.ai's medical imaging AI innovations. AI has the potential to power the early diagnosis of lung cancer giving the best chance of survival outcomes and improving quality of life for patients."
David M. Rubin
Managing Director
Merck Global Health Innovation Fund LLC
Let's talk oncology at ESMO 2026.
Discover how AI can connect detection, patient tracking and treatment action across the oncology journey. Meet Qure.ai on-site to explore the pathway.
Visit us at Booth #8097
